国产精品视频观看,又大又粗有色,琪琪吊操人妻日韩精品,欧美 国产 日韩成人

服務(wù)熱線

15021010459
技術(shù)文章
當(dāng)前位置:主頁 > 技術(shù)文章 > 賽諾菲投資7億美元支持Alnylam開發(fā)RNAi療法

賽諾菲投資7億美元支持Alnylam開發(fā)RNAi療法

更新時間:2014-01-14 點擊次數(shù):1594

    2014年1月14日賽諾菲宣布將擴大與Alnylam公司在RNAi研究領(lǐng)域的合作。公司將投入約7億美元收購Ainylam公司約12%的股份以支持其目前處于研發(fā)階 段的各種研究項目。這一動作同時也標(biāo)志著賽諾菲在波士頓地區(qū)繼續(xù)擴大影響。公司此前以200億美元的價格收購了Genzyme公司,而Genzyme公司將與Ainylam在RNAi領(lǐng)域開始密切配合。

    事實上,不僅僅是賽諾菲,一些制藥*都已經(jīng)開始表現(xiàn)出重返RNAi療法研究的跡象。例如羅氏公司剛剛簽訂了第二份關(guān)于RNAi研究的合作協(xié)議。這些跡象都暗示著今后這些醫(yī)藥研發(fā)*將可能向RNAi療法這一研究領(lǐng)域投入巨大精力。

詳細英文報道:

Sanofi is doubling down on its RNAi development deal with Alnylam. The pharma giant ($SNY) says it will pay a hefty premium to buy up a 12% stake in the biotech, investing $700 million and greatly expanding its rights to Alnylam's ($ALNY) lead drug along with a portfolio of current and prospective therapies.

The deal highlights Big Pharma's return to RNAi, a new technology for gene silencing that experienced a deep chill several years ago as Roche ($RHHBY) and others bowed out of the field. But Roche recently struck its second RNAi pact and Sanofi clearly believes that the industry is nearing some critical product-development milestones.

The expanded partnership also spotlights Sanofi's growing involvement in the Boston hub, where it paid $20 billion for Genzyme and its rare disease drugs. Now the Genzyme subsidiary will work with Alnylam on patisiran, in development for TTR-familial amyloid polyneuropathy, gaining marketing rights outside of North America and Europe. Sanofi also gains marketing rights to three other therapies in the pipeline while nabbing options on all other products that treat rare diseases.

Alnylam execs have been one of the chief proponents of RNAi as the next big product arena, with potential to rival monoclonal antibodies in terms of revenue potential. And they clearly relished the opportunity to boast about the new deal at the beginning of the big JPMorgan conference in San Francisco.

"RNAi therapeutics now have the opportunity to be the next product platform," Alnylam COO Barry Greene told Reuters.——(華雅干細胞整理報道)

2025 版權(quán)所有 © 重慶市華雅干細胞技術(shù)有限公司  備案號:渝ICP備14000349號-4 sitemap.xml 管理登陸 技術(shù)支持:化工儀器網(wǎng)

地址:重慶市江北區(qū)金渝大道153號8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

重慶市華雅干細胞技術(shù)有限公司主要經(jīng)營干細胞研究 干細胞治療產(chǎn)品 生物試劑 實驗耗材 藥物研發(fā)等產(chǎn)品。

關(guān)注我們

服務(wù)熱線

400-021-2200

掃一掃,關(guān)注我們

一级精品视频国产| 天堂在线/中文在线资源官网 | 超碰白嫩亚洲| 亚洲av无码专区首页| 鄂托克前旗| 无码无码专区手机在线观看| 中文字幕精品无码| 色欲婷婷欧美一区不卡| 亚洲欧美自拍视频| 国产一区久久88| 亚洲中文字幕无码永久不卡软件 | 日韩黄色视屏在线观看| 999国产精品| 伊人色五月丁香| 乡村舌L伦HD| 国产亚洲综合精品电影| 国产精品偷伦免费观看视频| 亚洲一区二禽兽呦呦| 色妞色综合久久夜夜| 男人天堂久久| 一本久久综合亚洲鲁鲁五月天 | 亚洲欧美混合| 一区二区三区精品国产欧美| 黄色大片在线观看| 午夜一级精品无码免费毛片| 四虎永久免费毛片| 最新中文无码精品A∨在线| 夜夜艹香蕉爱| 丁香五月综合啪| 亚洲欧美日韩综合一区久久| 日韩少妇无码| 久久精品夜色噜噜亚洲Av| 免费网址GV| 国产三区四区中文字幕| 色综合久久久网| 天天日天天射草| 淫人大香蕉视频| 国产av东京热| 亚洲天堂狠狠操| 四虎影视精品在线| 第二页亚洲AV最新乱码|